Skip to main content
88kviews
Editorial23 November 2022
Editorial: Innate lymphocytes in tumor surveillance

growth depending on the environmental conditions. The differential effects of ILCs on tumor outcome have been attributed to the high degree of heterogeneity and plasticity within the ILC family members. However, it is now becoming clear that ILC responses are shaped by their dynamic crosstalk with the different components of the tumor microenvironment (TME) (Jacquelot et al., 2022). Recent years have witnessed a significant development in the current understanding of ILCs and their roles in the innate immune system, where they regulate tissue homeostasis, inflammation, as well as tumor surveillance and tumorigenesis (Bal et al., 2020).ILCs may be classified into three subgroups depending on their phenotypic and functional characteristics: Group 1 ILCs, which include NK cells and ILC1s (Crinier et al., 2021); Group 2 ILCs, which only contain ILC2s (Kabata et al., 2018), and Group 3 ILCs, which comprise of LTi cells and ILC3s (Domingues and Hepworth, 2020). This research topic features several review and original research articles on the different facets of innate lymphocytes in the context of cancer. This includes basic underlying mechanisms of anti-tumor action as well as translational and clinical advances in this area of research. The topic spans different areas of NK cell as well as ILC research with emphasis on their role during tumor development and progression.NK cells are the prototype innate lymphoid cells exhibiting potent cytolytic function that provide host defense against infection and tumors. They are able to kill tumor cells if these show surface markers associated with oncogenic transformation. Due to this property NK cells control tumor growth at least in the early phase of tumor development and thus they 2 are essential in tumor surveillance. Once target cells are recognized the balance of activating and inhibitory receptor signaling regulates their effector function against tumor targets (Freud et al., 2017). These properties and their capacity to enhance antibody and T cell responses highlight the role for NK cells as anticancer agents (Pahl and Cerwenka, 2017;Shimasaki et al., 2020). Current research is focused on investigating how NK cells may be manipulated and employed as therapeutic strategies for the treatment of cancer. As mentioned above multiple approaches are being investigated to relieve NK cell immunosuppression in the tumor microenvironment. Immune checkpoint blockade inhibiting the programmed death-1 (PD-1) / programmed death-ligand 1 (PD-L1) axis seems not only acting on T cells but also on NK cells. However, the role of NK cells in PD-1/PD-L1 context is still a matter of debate (Cho et al., 2020). Del Rio, Perez-Simon and Rodriguez-Barbosa aimed to address this topic and present data from a mouse xenograft model suggesting that NK cell anti-tumor function is independent of PD-L1 expression on A20 tumor cells.ILCs regulate immune responses by responding and integrating diverse signals within local microenvironments and as such are ideally suited to sense malignant transformation and regulate tumor immunity. However, as ILCs have been associated with anti-tumor and protumor activities, they have been suggested to exert dual functions during carcinogenesis by promoting or suppressing the malignant outgrowth of premalignant lesions. Warner et al.discusses emerging evidence that shows that ILCs can impact early tumor development by regulating immune responses against transformed cells, as well as the environmental cues that influence ILC activation in premalignant lesions.Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. However, the role of the ILCs in HCC is still not well defined. Bouyarou and Golub provide an overview of the known roles and actions of ILCs in HCC with an emphasis on the importance of diverse signaling pathways in the tuning of their responses.ILCs are preferentially enriched in barrier tissues such as the skin, with emerging evidence indicating their role in the control of melanoma. Wagner and Koyasu review the current understanding of ILCs role as the first line of defence against melanoma development and progression and discuss the possibility to harness their therapeutic potential.ILC2s are important mediators of type 2 immunity and play important roles in allergic diseases, helminth infections, and tissue fibrosis (Helfrich et al., 2019). Studies over the past decade have reported that ILC2s exert context-dependent roles in cancer. Wu et al. review the roles of ILC2s in solid tumors and propose that ILC2s could serve as a predictor for tumor prognosis and a new therapeutic target after immunotherapy resistance.Despite the growing body of research on ILCs, there are still plenty of knowledge gaps of how these cells are shaped by disease-and tissue-specific cues. This research topic features several articles that highlight our current knowledge about ILCs in tumor surveillance, pinpoint gaps in our understanding and discuss the possibilities to harness their therapeutic potential.

1,988 views

2 citations

Natural killer (NK) cells belong to the family of innate immune cells with the capacity to recognize and kill tumor cells. Different phenotypes and functional properties of NK cells have been described in tumor patients, which could be shaped by the tumor microenvironment. The discovery of HLA class I-specific inhibitory receptors controlling NK cell activity paved the way to the fundamental concept of modulating immune responses that are regulated by an array of inhibitory receptors and emphasized to explore the potential of NK cells in cancer therapy. Despite a number of NK cell-based approaches are currently developed, many challenges have to be overcome for improved efficacy of these therapies, such as escape of tumor cells from NK cell recognition due to their expression of inhibitory molecules, immune suppressive signals of NK cells, reduced NK cell infiltration of tumors, an immune suppressive micromilieu and limited in vivo persistence of NK cells. Therefore, this review provides an overview about the NK cell biology, alterations of NK cell activities, changes in tumor cells and the tumor microenvironment contributing to immune escape or immune surveillance by NK cells and their underlying molecular mechanisms as well as the current status and novel aspects of NK cell-based therapeutic strategies including their genetic engineering and their combination with conventional treatment options to overcome tumor-mediated evasion strategies and improve therapy efficacy.

8,569 views

44 citations

The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance
Signal transducer and activator of transcription 3 (STAT3) is a member of the Janus kinase (JAK)–STAT pathway, which is one of the key pathways contributing to cancer. STAT3 regulates transcription downstream of many cytokines including interleukin (IL)-6 and IL-10. In cancer, STAT3 is mainly described as a tumor promoter driving tumor cell proliferation, resistance to apoptosis, angiogenesis and metastasis and aberrant activation of STAT3 is associated with poor prognosis. STAT3 is also an important driver of immune evasion. Among many other immunosuppressive mechanisms, STAT3 aids tumor cells to escape natural killer (NK) cell-mediated immune surveillance. NK cells are innate lymphocytes, which can directly kill malignant cells but also regulate adaptive immune responses and contribute to the composition of the tumor microenvironment. The inborn ability to lyse transformed cells renders NK cells an attractive tool for cancer immunotherapy. Here, we provide an overview of the role of STAT3 in the dynamic interplay between NK cells and tumor cells. On the one hand, we summarize the current knowledge on how tumor cell-intrinsic STAT3 drives the evasion from NK cells. On the other hand, we describe the multiple functions of STAT3 in regulating NK-cell cytotoxicity, cytokine production and their anti-tumor responses in vivo. In light of the ongoing research on STAT3 inhibitors, we also discuss how targeting STAT3 would affect the two arms of STAT3-dependent regulation of NK cell-mediated anti-tumor immunity. Understanding the complexity of this interplay in the tumor microenvironment is crucial for future implementation of NK cell-based immunotherapies.

11,113 views

58 citations

MINI REVIEW
3 June 2022
Role of ILC2s in Solid Tumors: Facilitate or Inhibit?
Lige Wu, 4 more and Xin Yang

5,298 views

18 citations

ORIGINAL RESEARCH
18 January 2022
Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity
Nicola Tumino, 14 more and Paola Vacca

11,478 views

54 citations